Multiplex-nested RT-PCR to evaluate latent and lytic Epstein Barr virus gene expression

Journal of Biotechnology

Volumn 128, Issue 3, 2007, Pages 462-476

  Bergallo, Massimiliano ^a   Costa, Cristina ^a   Baro, Sara ^a   Musso, Tiziana ^a   Balbo, Luciano ^b   Merlino, Chiara ^a   Cavallo, Rossana ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

EBV; EBV related disease; Latent lytic EBV gene expression; Multiplex nested RT PCR

Indexed keywords

CELL CULTURE; DISEASES; IMMUNOLOGY;

GENE EXPRESSION; IMMUNOCOMPROMISED HOSTS; IMMUNOSUPPRESSED PATIENTS; LATENT/LYTIC EBV GENE EXPRESSION; MULTIPLEX-NESTED RT-PCR;

GENETIC ENGINEERING;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GRAFT RECIPIENT; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER GRAFT; LYMPHOPROLIFERATIVE DISEASE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS; VIRUS GENE; VIRUS INFECTION; VIRUS TRANSCRIPTION;

ADULT; AGED; CELLS, CULTURED; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS LATENCY; VIRUS REPLICATION;

EQUUS SUBG. HIPPOTIGRIS; HUMAN HERPESVIRUS 4;

EID: 33846343623     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2006.11.005     Document Type: Article

References (22)

1. Amon W., and Farrell P.J. Reactivation of Epstein-Barr virus from latency. Rev. Med. Virol. 15 (2005) 149-156
2. Babcock G.J., Hochberg D., and Thorley-Lawson D.A. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13 (2000) 497-506
3. Bergallo M., Merlino C., Daniele R., Sinesi F., Fumagalli M., Negro Ponzi A., and Cavallo R. Double-step PCR assay to quantify Epstein Barr viral load in peripheral blood. Mol. Biotechnol. 27 (2004) 187-195
4. Brink A.T.P., Oudejans J.J., Jiwa M., Walboomers J.M.M., Meijer C.J.L.M., and van den Brule A.J.C. Multiprimed cDNA synthesis followed by PCR is the most suitable method for Epstein-Barr virus transcript analysis in small lymphoma biopsies. Mol. Cell. Probes 11 (1997) 39-47
5. Callan M.F.C. The immune response to Epstein-Barr virus. Microb. Infect. 6 (2004) 937-945
6. Decker L.L., Klaman L.D., and Thorley-Lawson D.A. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J. Virol. 70 (1996) 3286-3289
7. Fahmi H., Cochet C., Hmama Z., Opolon P., and Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein Barr Virus BZLF1 immediate-early Gene product ZEBRA by an in direct mechanism which requires the MAPK kinase pathway. J. Virol. 74 (2000) 5810-5818
8. Feng W.H., Israel B., Raab-Traub N., et al. Chemotherapy induces lytic EBV replication and conferì ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62 (2002) 1920-1926
9. Iwatsuki K., Yamamoto T., Tsuji K., Suzuki D., Fujii K., Matsuura H., et al. A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med. Okayama 58 (2004) 169-180
10. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3 (2003) 801-812
11. Niller H.H., Salamon D., Ilg K., Koroknai A., Banati F., Schwarzmann F., Wolf H., et al. EBV-associated neoplasms: alternative pathogenetic pathways. Med. Hypothesis 62 (2004) 387-391
12. Prang N.S., Hornef M.W., Jäger M., Wagner H.J., Wolf H., and Schwarzmann F.M. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 89 (1997) 1665-1677
13. Qu L., Green M., Webber S., Reyes J., Ellis D., and Rowe D. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J. Infect. Dis. 182 (2000) 1013-1021
14. Rickinson A.B., and Kieff E. Epstein-Barr virus. In: Knipe D.M., and Howley P.M. (Eds). Fields-Virology vol. 2 (2001), Lippincott Williams Wilkins Publishers, Philadelphia 2575-2628
15. Rowe M., Niedobitek G., and Young L. EBV gene expressionin posttransplant lymphoproliferative disorders. Springer Semin. Immunopathol. 20 (1998) 389-403
16. Rowe D.T. Epstein-Barr virus immortalization and latency. Fron. Biosci. 4 (1999) D346-D371
17. Tierney R.J., Steven N., Young L.S., and Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 78 (1994) 7374-7385
18. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1 (2001) 75-82
19. Tsurumi T., Fujiita M., and Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev. Med. Virol. 15 (2005) 3-15
20. Westphal E.M., Blackstock W., Feng W., et al. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60 (2000) 5781-5788
21. Young S.L., and Murray P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22 (2003) 5108-5121
22. Young S.L., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. 4 (2004) 757-768